Company CVAbout Cohance Lifesciences Ltd 
Cohance Lifesciences Ltd
Small Cap
Pharmaceuticals & Biotechnology
Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018. The name of the Company has been changed to Cohance Lifesciences Limited w.e.f. May 7, 2025. Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
Company Coordinates
No Company Details Available
Capital StructureCapital Structure
Present Equity Capital
INR 25.46 Cr
Number of Shares
25.46 Cr
Face Value
INR 1.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
25-Sep-2020
25.46
25.46
127282478
1
Bonus Issue
27-Jan-2020
12.73
12.73
127182478
1
Scheme of Arrangement
06-Nov-2018
1
0.01
100000
1
Subscriber to MOA
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
100
Mutual Funds
Held by 30 Schemes (16.49%)
FIIs
Held by 145 FIIs (6.51%)
Promoter with highest holding
Berhyanda Limited (33.34%)
Highest Public shareholder
Jasti Property And Equity Holdings Private Limited (6.57%)
Individual Investors Holdings
6.42%
Board of Directors
Management
Designation
Remuneration
Venkateswarlu Jasti
Managing Director
9.82 cr
Deepanwita Chattopadhyay
Independent Director
3.4 lacs
V Sambasiva Rao
Independent Director
3.8 lacs
Jerry Jeyasingh
Non-Exec & Non-Independent Dir
0
Hanumantha Rao Kokkonda
Company Secretary
0
D G Prasad
Independent Director
5.6 lacs
J V Ramudu
Chairman & Non Executive Dir.
6.0 lacs
Shweta Jalan
Non Executive Director
0
U B Pravin Rao
Independent Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Packing Materials Consumed
4.55
0%
Packing Materials Consumed
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
No Data Available for Finished Goods Segmentation
No Data Available
Stock DNARevenue and Profits:
Net Sales:
556 Cr
(Quarterly Results - Sep 2025)
Net Profit:
74 Cr
Pharmaceuticals & Biotechnology
INR 20,687 Cr (Small Cap)
61.00
34
0.00%
0.01
9.08%
5.55
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
